Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M 4 Muscarinic Acetylcholine Receptor
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Christopher R Butler und 24 weiteren Autor:innen. Beteiligte Einrichtung: Medicine Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States. Hauptthemen laut MEDLINE: Receptor, Muscarinic M4, Drug Design, Brain. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Selective activation of the M4 muscarinic acetylcholine receptor subtype offers a novel strategy for the treatment of psychosis in multiple neurological disorders. Although the development of traditional muscarinic activators has been stymied due to pan-receptor activation, muscarinic receptor subtype selectivity can be achieved through the utilization of a subtype of a unique allosteric site. A major challenge in capitalizing on this allosteric site to date has been achieving a balance of suitable potency and brain penetration. Herein, we describe the design of a brain penetrant series of M4 selective positive allosteric modulators (PAMs), ultimately culminating in the identification of 21 (PF-06852231, now CVL-231/emraclidine), which is under active clinical development as a novel mechanism and approach for the treatment of schizophrenia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medicine Design, Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts 02139, United States.
- Internal Medicine, Pfizer Inc., Cambridge, Massachusetts 02139, United States.
- Medicine Design, Medicinal Chemistry, Pfizer Inc., Groton, Connecticut 06340, United States.
- Medicine Design, Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States.
- Discovery Sciences, Primary Pharmacology, Pfizer Inc., Groton, Connecticut 06340, United States.
ORCID-Profile: Christopher R Butler, Michael Popiolek, Laura A McAllister, Michael A Brodney, Adam Gilbert
Zitieren
APA
Butler, C. R., Popiolek, M., McAllister, L. A., LaChapelle, E. A., Kramer, M., Beck, E. M., Mente, S., Brodney, M. A., Brown, M., Gilbert, A., Helal, C., Ogilvie, K., Starr, J., Uccello, D., Grimwood, S., Edgerton, J., Garst-Orozco, J., Kozak, R., Lotarski, S., …, & Steyn, S. J. (2024). Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M 4 Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00293
Vancouver
Butler CR, Popiolek M, McAllister LA, LaChapelle EA, Kramer M, Beck EM, et al. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M 4 Muscarinic Acetylcholine Receptor. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00293
BibTeX
@article{Butler2024,
author = {Butler, Christopher R and Popiolek, Michael and McAllister, Laura A and LaChapelle, Erik A and Kramer, Melissa and Beck, Elizabeth M and Mente, Scot and Brodney, Michael A and Brown, Matthew and Gilbert, Adam and Helal, Chris and Ogilvie, Kevin and Starr, Jeremy and Uccello, Daniel and Grimwood, Sarah and Edgerton, Jeremy and Garst-Orozco, Jonathan and Kozak, Rouba and Lotarski, Susan and Rossi, Amie and Smith, Deborah and O'Connor, Rebecca and Lazzaro, John and Steppan, Claire and Steyn, Stefanus J},
title = {Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M 4 Muscarinic Acetylcholine Receptor},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00293}
}
EUVIMED